Evidence for role of prostacyclin as a systemic hormone in portal hypertension

J. V. Sitzmann, S. S. Li, N. F. Adkinson

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


The possibility that prostacyclin could be a systemic hormone and could mediate the splanchnic hyperemia of chronic portal hypertension was evaluated in rabbits in a normotensive state and in rabbits with chronic partial ligation of the portal vein. In rabbits with portal hypertension (PHT), 6-keto-prostaglandin F(1α) (PGF(1α), a prostacyclin degradation product) was elevated twofold in all vascular beds (systemic arterial, systemic venous, and portal venous) when compared with levels in control animals. In PHT rabbits, exogenous prostacyclin infusion after cyclooxygenase blockade through the systemic arterial, systemic venous, or portal venous route resulted in an equal elevation of 6-keto-PGF(1α) in the reciprocal vascular beds and restored the original precyclooxygenase blockade hemodynamics. These hemodynamic changes were of equal magnitude irrespective of site of infusion in PHT. In controls there was no significant change in 6-keto-PGF(1α) or hemodynamics with intraportal infusion. We conclude that prostacyclin achieves systemic levels by escaping hepatic degradation resulting from portosystemic shunting in the animal with chronic portal hypertension.

Original languageEnglish (US)
Pages (from-to)149-153
Number of pages5
Issue number2
StatePublished - 1991

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Evidence for role of prostacyclin as a systemic hormone in portal hypertension'. Together they form a unique fingerprint.

Cite this